The acquisition of Ellipse Technologies by NuVasive for $410 million—representing a staggering 10x sales multiple—remains a gold standard for orthopedic startups. While the industry saw the exit, I saw the engine behind it.
I joined Ellipse in 2012 as employee #18 to lead R&D. Over the following four years, the company doubled its business annually by executing a high-stakes playbook. Below are the 10 cultural pillars that defined the Ellipse DNA and enabled its remarkable growth.
1. Master the Pivot
Ellipse didn’t start in orthopedics; it began as a cardiac spin-off focused on bariatric...
